...All right. Great, everybody. We're going to get going with the next session. I'm Matthew Harrison, one of the Biotech Analysts here at Morgan Stanley. Very pleased to have Doug Ingram, the CEO of Sarepta with me for the next session. Just briefly before we get started, I have to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. Doug has promised that he is going to read the FDA communication for us. That will entail the entire session. No, sorry....